ZEFER and H2ME deliver 100 hydrogen taxis to Copenhagen and achieve a key milestone for transport in Europe
21.4.2022 11:00:00 EEST | Business Wire | Press release
Two pan-European projects have collaborated to bring zero emission hydrogen taxis and a new hydrogen refuelling station to the Danish capital city.
The ZEFER (Zero Emission taxi Fleets for European Rollout) and H2ME2 (Hydrogen Mobility Europe) projects, both funded by Europe’s Clean Hydrogen Partnership1, have deployed 100 hydrogen taxis in Copenhagen with app-based taxi company DRIVR. The Toyota Mirais run on green hydrogen from renewable energy, following the installation and opening of a new hydrogen refuelling station (HRS) in the city.
This latest deployment of taxis means the wider ZEFER project has achieved its full complement of 180 FCEVs in high-utilisation, captive fleets across Europe with deployments in three capital cities (Paris, London and Copenhagen). The taxi deployment in Copenhagen will complement 60 taxis previously deployed to Hype by STEP in Paris, and 60 other passenger cars in London deployed between private-hire firm Green Tomato Cars (50) and the Metropolitan Police (10).
To date the 120 vehicles operated under the ZEFER project have driven over 7 million kilometres fuelled only by hydrogen. This high mileage is achieved as the project deliberately targets the very long daily mileage applications which are most suitable to hydrogen vehicles. They have achieved this without major safety or reliability incidents and vehicle performance has been rated highly by drivers and fleet managers, with limited breakdowns or issues encountered relating directly to the hydrogen drivetrain.
The Danish government have targeted all taxis to be zero emission by 2030 and DRIVR won the public tender to deliver ad-hoc taxi services in the City of Copenhagen. The 100 new hydrogen taxis will complement DRIVR's existing low emission fleet, already comprising hybrid, electric and hydrogen vehicles.
“We are incredibly proud that DRIVR has been entrusted with the important task of helping the municipality of Copenhagen reach its environmental goals, and we’re very grateful for the cooperation with Toyota, which has enabled us to meet their needs with the new Toyota Mirai hydrogen cars.” said Haydar Shaiwandi, CEO DRIVR.
“While aiming to deploy its platform in 15 new cities by 2024, Hype believes that hydrogen is one of the most relevant solutions for intensive and random mobility and that the taxi market can play a key role in accelerating the adoption of hydrogen by professionals at scale. We are glad to see DRIVR ramping up the integration of hydrogen among its solutions. This demonstrates that, thanks to the support of programmes such as ZEFER, an increasing number of players are taking the hydrogen path. Early adopters will definitely have an advantage and leverage their experience moving forward.” said Mathieu Gardies, President of Hype.
- Ends -
Notes to Editor
1 previously Fuel Cell and Hydrogen 2 Joint Undertaking (FCH2 JU)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005150/en/
Contact information
Declan Shepherd
info@zefer.eu
01509 642 500
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin ® Delivery System for Overactive Bladder28.4.2026 15:42:00 EEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 15:28:00 EEST | Press release
CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 15:11:00 EEST | Press release
BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427537841/en/ Thomas Coesfeld and Bob Valentine, Courtesy of BMG and Concord The combination comes amid significant transformation in the global music market, where scale, global reach, and technology investment are increasingly critical to remain competitive. Together, BMG and Concord will form a fully integrated global music company spanning music publishing, recorded music, theatrical rights, and digital distribution. This increased scale will enable deeper investment
Masimo SET ® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 15:00:00 EEST | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi, Jackson, alongside online publication in the Journal of Pediatrics. As the authors noted, “[W]e found no evidence of clinically meaningful skin tone-related discrepancies, suggesting equitable monitoring performance for this device in this clinical setti
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 12:54:00 EEST | Press release
KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428825343/en/ KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center Jury panels from both awards highlighted the AI Compute Pod's excellence in miniaturization, modularity, and intelli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom